KR20040083471A - 노인성 우울증의 치료에서 카르니틴의 용도 - Google Patents
노인성 우울증의 치료에서 카르니틴의 용도 Download PDFInfo
- Publication number
- KR20040083471A KR20040083471A KR10-2004-7009147A KR20047009147A KR20040083471A KR 20040083471 A KR20040083471 A KR 20040083471A KR 20047009147 A KR20047009147 A KR 20047009147A KR 20040083471 A KR20040083471 A KR 20040083471A
- Authority
- KR
- South Korea
- Prior art keywords
- carnitine
- acid
- pharmaceutically acceptable
- medicament
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229960004203 carnitine Drugs 0.000 title claims abstract description 12
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 title 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 27
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- -1 alkanoyl L-carnitine Chemical compound 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 20
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 235000021317 phosphate Nutrition 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
- 229940009098 aspartate Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 4
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 claims description 3
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims description 2
- 150000003893 lactate salts Chemical class 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000935 antidepressant agent Substances 0.000 abstract description 5
- 229940005513 antidepressants Drugs 0.000 abstract description 4
- 230000000994 depressogenic effect Effects 0.000 description 13
- 230000003001 depressive effect Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 150000004713 phosphodiesters Chemical class 0.000 description 10
- 150000003904 phospholipids Chemical class 0.000 description 9
- 210000004227 basal ganglia Anatomy 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 5
- 230000002360 prefrontal effect Effects 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000024714 major depressive disease Diseases 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- INAPMGSXUVUWAF-UOTPTPDRSA-N 1D-myo-inositol 1-phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-UOTPTPDRSA-N 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000011736 mal de Debarquement Diseases 0.000 description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CFPWPNDPUSLDPF-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]-2-phosphonoacetic acid Chemical compound NC(=N)N(C)C(C(O)=O)P(O)(O)=O CFPWPNDPUSLDPF-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JATPLOXBFFRHDN-DDWIOCJRSA-N [(2r)-2-acetyloxy-3-carboxypropyl]-trimethylazanium;chloride Chemical compound [Cl-].CC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C JATPLOXBFFRHDN-DDWIOCJRSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000000782 polymeric membrane extraction Methods 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- JZNWSCPGTDBMEW-YFKPBYRVSA-N sn-glycero-3-phosphoethanolamine Chemical compound NCCO[P@@](O)(=O)OC[C@@H](O)CO JZNWSCPGTDBMEW-YFKPBYRVSA-N 0.000 description 1
- 238000000264 spin echo pulse sequence Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35432302P | 2002-02-07 | 2002-02-07 | |
| US60/354.323 | 2002-02-07 | ||
| PCT/IT2003/000023 WO2003066041A1 (en) | 2002-02-07 | 2003-01-23 | Carnitine in the treatment of geriatric depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20040083471A true KR20040083471A (ko) | 2004-10-02 |
Family
ID=27734357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2004-7009147A Ceased KR20040083471A (ko) | 2002-02-07 | 2003-01-23 | 노인성 우울증의 치료에서 카르니틴의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040009926A1 (https=) |
| EP (1) | EP1471904A1 (https=) |
| JP (1) | JP2005523269A (https=) |
| KR (1) | KR20040083471A (https=) |
| AR (1) | AR038350A1 (https=) |
| AU (1) | AU2003219511A1 (https=) |
| CA (1) | CA2469925A1 (https=) |
| MX (1) | MXPA04007506A (https=) |
| PL (1) | PL374082A1 (https=) |
| WO (1) | WO2003066041A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407778B2 (en) | 2002-02-07 | 2008-08-05 | Pettegrew Jay W | Compounds, compositions and methods for treating neuropsychiatric disorders |
| US7700074B2 (en) | 2002-02-07 | 2010-04-20 | Pettegrew Jay W | Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism |
| US20050272812A1 (en) * | 2002-02-07 | 2005-12-08 | Pettegrew Jay W | Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans |
| US7815894B2 (en) | 2003-05-29 | 2010-10-19 | Jay W. Pettegrew | Compounds, compositions and methods for medical imaging of neuropsychiatric disorders |
| MX2012014127A (es) | 2010-06-16 | 2013-06-28 | Sigma Tau Ind Farmaceuti | Acetil-carnitina para uso en un metodo para incrementar neurogenesis en tejido nervioso. |
| EP3212191B1 (en) * | 2014-10-28 | 2022-10-05 | Medlab IP Pty Ltd. | Treatment for depression and depressive disorders |
| US11918336B2 (en) * | 2019-02-19 | 2024-03-05 | King Abdullah University Of Science And Technology | Reduced feature generation for signal classification based on position weight matrix |
| KR20230011999A (ko) | 2020-05-15 | 2023-01-25 | 알파시그마 에스.피.에이. | 메틸폴레이트를 포함하는 조성물 |
| CA3238205A1 (en) * | 2021-11-12 | 2023-05-19 | Rajaram Samant | A synergistic composition for activating intracellular secondary messenger(camp) pathway |
| CN117797134A (zh) * | 2022-09-23 | 2024-04-02 | 合肥瀚微生物科技有限公司 | 一种4-tmap治疗或缓解抑郁症的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
| US5208037A (en) * | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
| US5879884A (en) * | 1994-12-29 | 1999-03-09 | Peroutka; Stephen J. | Diagnosis of depression by linkage of a polymorphic marker to a segment of chromosome 19P13 bordered by D19S247 and D19S394 |
| JP3425276B2 (ja) * | 1995-08-11 | 2003-07-14 | 株式会社日立製作所 | 情報通知システム |
| JPH10143640A (ja) * | 1996-11-15 | 1998-05-29 | Nippon Lsi Card Kk | 携帯コンピュータ及びそれを用いた情報管理システム並びにそれを用いた立体地図の作成方法 |
| US5889055A (en) * | 1997-04-04 | 1999-03-30 | Howard; James R. | L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism |
-
2003
- 2003-01-23 AU AU2003219511A patent/AU2003219511A1/en not_active Abandoned
- 2003-01-23 PL PL03374082A patent/PL374082A1/xx unknown
- 2003-01-23 CA CA002469925A patent/CA2469925A1/en not_active Abandoned
- 2003-01-23 WO PCT/IT2003/000023 patent/WO2003066041A1/en not_active Ceased
- 2003-01-23 EP EP03715324A patent/EP1471904A1/en not_active Withdrawn
- 2003-01-23 KR KR10-2004-7009147A patent/KR20040083471A/ko not_active Ceased
- 2003-01-23 MX MXPA04007506A patent/MXPA04007506A/es unknown
- 2003-01-23 JP JP2003565465A patent/JP2005523269A/ja active Pending
- 2003-02-05 AR ARP030100356A patent/AR038350A1/es unknown
- 2003-02-07 US US10/359,560 patent/US20040009926A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2469925A1 (en) | 2003-08-14 |
| AR038350A1 (es) | 2005-01-12 |
| AU2003219511A1 (en) | 2003-09-02 |
| US20040009926A1 (en) | 2004-01-15 |
| JP2005523269A (ja) | 2005-08-04 |
| EP1471904A1 (en) | 2004-11-03 |
| PL374082A1 (en) | 2005-09-19 |
| MXPA04007506A (es) | 2004-11-10 |
| WO2003066041A1 (en) | 2003-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Willemsen et al. | Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome | |
| Friedman et al. | Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder | |
| US20220152058A1 (en) | Methods and compositions for treating various disorders | |
| Bartzokis et al. | Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study | |
| JP2020073529A (ja) | デクスメデトミジンを用いて小児患者を治療する方法 | |
| US20100041621A1 (en) | Methods and compositions for improving cognitive performance | |
| KR20040083471A (ko) | 노인성 우울증의 치료에서 카르니틴의 용도 | |
| KR20160124246A (ko) | 성기능장애의 치료에서의 테스토스테론과 ｈｔ1ａ 작용제의 용도 | |
| BR112020011055A2 (pt) | tetratiomolibdato de bis-colina para tratar doença de wilson | |
| JP2021527090A (ja) | 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物 | |
| Moore et al. | Effects of myo-inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study | |
| Frederick et al. | Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline | |
| MXPA06004081A (es) | Lipolisis local medicamentosa dirigida. | |
| Al-Samsam et al. | Extracellular N-acetyl-aspartate as a biochemical marker of the severity of neuronal damage following experimental acute traumatic brain injury | |
| Schmitz et al. | Resuscitation from cardiac arrest in cats: influence of epinephrine dosage on brain recovery | |
| JP2011116775A (ja) | 局所脳血流低下に伴う神経系障害の予防または治療のための医薬組成物 | |
| US8013016B2 (en) | Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome | |
| WO1999056750A1 (en) | Use of 4-piperidinemethanol derivatives in treatment of neurodevelopmental disorders | |
| US20250032514A1 (en) | Compositions and methods for the treatment of various diseases | |
| WO2024073794A1 (en) | SUBJECT SELECTION FOR 11β-HSD1 INHIBITOR TREATMENT | |
| Coit et al. | A Placebo-Controlled Trial of Acetyl-L-Carnitine and α-Lipoic Acid in the Treatment of Bipolar Depression | |
| Scott | Childhood status epilepticus: structural consequences and assessment of a novel treatment | |
| Vulink et al. | Positron emission tomography imaging of amphetamine-induced dopamine release in drug-free patients with obsessive-compulsive disorder: preliminary findings | |
| Korinthenberg | for Neuropediatrics (Gesellschaft für Neuropädiatrie) April 4±7, 2002, Freiburg/Breisgau, Germany | |
| Becker et al. | Safety and target engagement profile of two oxaloacetate doses in Alzheimer’s patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20040612 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20071204 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20090706 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20090914 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20090706 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |